Amiloride
( DrugBank: Amiloride / KEGG DRUG: Amiloride hydrochloride, Amiloride )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis | 5 |
| 67 | Polycystic kidney disease | 2 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 225 | Congenital nephrogenic diabetes insipidus | 4 |
| 299 | Cystic fibrosis | 3 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
67. Polycystic kidney disease
Clinical trials : 233 / Drugs : 188 - (DrugBank : 54) / Drug target genes : 60 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
225. Congenital nephrogenic diabetes insipidus
Clinical trials : 17 / Drugs : 40 - (DrugBank : 19) / Drug target genes : 33 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
299. Cystic fibrosis
Clinical trials : 1,826 / Drugs : 1,271 - (DrugBank : 246) / Drug target genes : 118 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|